Abbott’s Kazemi discusses a decade of diabetes advancements and the impact of CGM on diabetes care
In this episode of AbbottTalks, Mahmood Kazemi, MD, Chief Medical Officer of Abbott’s Diabetes Care business overviews the profound advancements in diabetes management over the past decade and discusses the evolution of treatments and technological innovations that have revolutionized how individuals with diabetes approach their condition.
Further, Dr. Kazemi underscores the benefits of advancements such as the GLP-1 receptor agonists and medications that control glucose levels and offer cardiovascular and renal protection. He then elaborates on how Abbott's FreeStyle Libre continuous glucose monitoring (CGM) systems have significantly improved diabetes management. These systems provide real-time data, empowering individuals to customize their medication, diet, and activity levels with unprecedented precision. He also speaks to Abbott's ongoing and future work, including developing a state-of-the-art continuous glucose ketone monitoring (CGKM) sensor. This medical biowearable is designed to provide crucial early warning signs in Type 1 diabetes management, a significant step towards preventing dangerous complications and hospitalizations.
Looking to the future, Kazemi anticipates a wider adoption of CGM across the diabetes community, including those with type 2 diabetes, and an increase in insurer coverage.
Thank you to BMP Medical for sponsoring this episode of AbbottTalks! For more information on how BMP Medical works with medical device companies, visit www.bmpmedical.com
Thank you for listening to the AbbottTalks Podcast. Tune in and subscribe to DeviceTalks on all major podcast channels to never miss an episode.
Further, Dr. Kazemi underscores the benefits of advancements such as the GLP-1 receptor agonists and medications that control glucose levels and offer cardiovascular and renal protection. He then elaborates on how Abbott's FreeStyle Libre continuous glucose monitoring (CGM) systems have significantly improved diabetes management. These systems provide real-time data, empowering individuals to customize their medication, diet, and activity levels with unprecedented precision. He also speaks to Abbott's ongoing and future work, including developing a state-of-the-art continuous glucose ketone monitoring (CGKM) sensor. This medical biowearable is designed to provide crucial early warning signs in Type 1 diabetes management, a significant step towards preventing dangerous complications and hospitalizations.
Looking to the future, Kazemi anticipates a wider adoption of CGM across the diabetes community, including those with type 2 diabetes, and an increase in insurer coverage.
Thank you to BMP Medical for sponsoring this episode of AbbottTalks! For more information on how BMP Medical works with medical device companies, visit www.bmpmedical.com
Thank you for listening to the AbbottTalks Podcast. Tune in and subscribe to DeviceTalks on all major podcast channels to never miss an episode.
Activity